



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	10/627,358
Filing Date	July 23, 2003
First Named Inventor	Peter Migaly
Art Unit	Art Unit 1614
Examiner Name	Eric Olson
Attorney Docket Number	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/ESO/		Azhar MZ Comparison of fluvoxamine alone, fluvoxamine and cognitive psychotherapy and psychotherapy alone in the treatment of panic disorder in Kelantan - implications for management by family doctors. Med J Malaysia 2000 55(4)402-8.	
/ESO/		Barlow DH Anxiety and its disorders (learned alarms) pages 220-225, Guilford Press, 1988	
/ESO/		Brody A. et al Regional brain metabolic changes in patients with major depression treated with either paroxetine or Interpersonal therapy. Arch Gen Psychiatry 2001; 58:631-640.	
/ESO/		Cremers TJ, et al Is the beneficial antidepressant effect of coadministration of pindolol really due to somatodendritic autoreceptor antagonism? Biol Psychiatry 2001 Jul 1; 50(1):13-21.	
/ESO/		Current Patents 15 Nov 2002 week 0246 at http://scientific.thompson.com/media/cd/journals/gazettenews/202/CPG_News_0246.pdf - enclosed]	
/ESO/		DeRubeis RJ et al Cognitive therapy vs Medications in the treatment of moderate to severe depression Arch Gen Psychiatry 2005; 62:409-416.	
/ESO/		Ferris RM et al Bupropion: a new antidepressant drug, the mechanism of action of which is not associated with downregulation of postsynaptic β -adrenergic, serotonergic (5-HT ₂), α 2-adrenergic, imipramine and dopaminergic receptors in brain. Neuropharmacology 22 No 11, 1257-1267, 1983.	
/ESO/		Goldapple K. et al Modulation of cortical-limbic pathways in major depression. Arch. Gen Psychiatry, Vol 61, Jan 2004, pages 34-41,	
/ESO/		Kramer MS et al The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. Arch Gen Psychiatry 1997; 54:567-572.	
/ESO/		Kuoppamaki M et al Differential regulation of rat 5-HT _{2A} and 5-HT _{2C} receptors after chronic treatment with clozapine, chlorpromazine and three putative atypical antipsychotic drugs. Neuropsychopharmacology 13:139-150, 1995.	

Examiner Signature	/Eric Olson/	Date Considered	08/22/2008
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2**Complete if Known**

Application Number	10/627,358
Filing Date	July 23, 2003
First Named Inventor	Peter Migaly
Art Unit	Art Unit 1614
Examiner Name	Eric Olson
Attorney Docket Number	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/ESO/		Landen M. et al A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry 1998; 59:664-668.	
/ESO/		Paton, C. Generic clozapine: outcomes after switching formulations. British Journal of Psychiatry 2006. 189 184-185	
/ESO/		Perez V et al A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Arch Gen Psychiatry. 1999; 56(4):375-379.	
/ESO/		Roth BL et al Chronic mianserine treatment decreases 5-HT2 receptor binding without altering 5-HT2 receptor mRNA levels. European Journal of Pharmacology - Molecular Pharmacology Section, 207 (1991) 169-172	
/ESO/		Sharp DM et al Global measures of outcome in controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care. Br J Gen Pract 1997 47(416) 150-5.	
/ESO/		Simon NM et al (Longitudinal outcome with pharmacotherapy in a naturalistic study of panic disorder. Journal of Affective Disorders 69 (2002) 201-208.	
/ESO/		Stoner, S.C. et al A program to convert patients from Trade-name to generic clozapine Pharmacotherapy 2003; 23(6):806-810 [particularly page 806 second column 3 rd line from the bottom on patent expiration	
/ESO/		Toth M et al Antagonist-mediated downregulation of 5-hydroxytryptamine type 2 receptor gene expression: Modulation of transcription. Molecular pharmacology 45:1095-1100, 1994.	

Examiner Signature	/Eric Olson/	Date Considered	08/22/2008
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.